Elisabet Stener-Victorin

My research group, Reproductive Endocrinology and Metabolism, conducts translational research aimed at providing a detailed understanding of the pathophysiology of polycystic ovary syndrome, including how the disorder arises, is inherited, and contributes to comorbidities across generations. A central focus is to dissect the molecular, mechanistic, and causal links connecting PCOS to reproductive complications such as implantation failure, early pregnancy loss, and endometrial cancer, as well as to metabolic disturbances, particularly insulin resistance and type 2 diabetes.

To identify the primary drivers of the disease, we use several well-established PCOS-like mouse models, in which exposures during critical developmental windows induce phenotypes that closely resemble human PCOS. In parallel, we conduct clinical studies where women with and without PCOS undergo detailed phenotyping, including comprehensive assessment of metabolic parameters, hormonal profiles, and reproductive function. Biological samples are systematically collected, including blood and serum, as well as tissue biopsies from the endometrium, subcutaneous adipose tissue, and skeletal muscle. These samples are used both to characterize disease heterogeneity and to investigate the effects of different treatments, including lifestyle interventions and pharmacological strategies.

At the molecular level, we perform high-resolution analyses of collected samples using techniques such as single-nuclei RNA sequencing and spatial transcriptomics, enabling cell-type-specific and spatially resolved mapping of gene expression in complex tissues. To functionally test identified mechanisms, we also establish primary human in vitro models, such as organoids and spheroids derived from patient tissues. These systems are used to experimentally manipulate identified signaling pathways and cellular processes, as well as to study cross-talk between different tissues and circulating factors.

By integrating animal models, advanced molecular analyses, and patient-based studies, we aim to generate a mechanistic understanding of PCOS, with the ultimate goal of identifying novel biomarkers and targeted therapeutic strategies.